Eric Angevin

Eric Angevin

UNVERIFIED PROFILE

Are you Eric Angevin?   Register this Author

Register author
Eric Angevin

Eric Angevin

Publications by authors named "Eric Angevin"

Are you Eric Angevin?   Register this Author

42Publications

1691Reads

26Profile Views

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 11 4;36(33):3298-3306. Epub 2018 Oct 4.

John H. Strickler, Duke University Medical Center, Durham, NC; Colin D. Weekes, University of Colorado, Aurora, CO; John Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Ramesh K. Ramanathan, Virginia Piper Cancer Center at Honor Health/Translational Genomics Research Institute, Scottsdale, AZ; Rebecca S. Heist, Massachusetts General Hospital Cancer Center, Boston, MA; Daniel Morgensztern, Washington University School of Medicine, St. Louis, MO; Eric Angevin, Gustave Roussy, Villejuif, France; Todd M. Bauer, Sarah Cannon Research Institute; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Huibin Yue, Daniel Afar, and Louie Naumovski, AbbVie Inc.; Apurvasena Parikh, Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Redwood City; Karen Kelly, University of California Davis Comprehensive Cancer Center, Sacramento, CA; and Monica Motwani, Edward B. Reilly, AbbVie Inc., North Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.7697
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.7697DOI Listing
November 2018

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Eur J Cancer 2018 03 3;92:1-10. Epub 2018 Feb 3.

Drug Development Department, Gustave Roussy, Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France; Gustave Roussy Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.020DOI Listing
March 2018

[Communication in the context of phase I clinical trials in oncology: implementation and evaluation of training programs].

Bull Cancer 2015 Feb 15;102(2):174-81. Epub 2015 Jan 15.

Institut Gustave-Roussy, département interdisciplinaire de soins de support aux patients en oncohématologie, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2014.12.013DOI Listing
February 2015

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.

Clin Cancer Res 2014 Jun 1;20(11):3012-22. Epub 2014 Apr 1.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France; Medizinische Hochschule Hannover, Hannover; Technische Universität München, Munich, Germany; Taichung Veterans General Hospital, National Yang-Ming University School of Medicine; National Taiwan University Hospital, Taipei, Taiwan; 12 de Octubre University Hospital, Madrid, Spain; University of California, San Francisco, San Francisco, California; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3006DOI Listing
June 2014

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 21;20(8):2192-204. Epub 2014 Feb 21.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Centre Francois Baclesse, CHU Côte de Nacre, Caen; Centre Léon Bérard Lyon, Lyon, France; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; 12 de Octubre University Hospital, Madrid, Spain; Fox Chase Cancer Center, Philadelphia; Janssen Research & Development, Spring House, Pennsylvania; formerly University of Texas, MD Anderson Cancer Center, Houston, Texas; currently UC San Diego Moores Cancer Center, San Diego, California; Erasme University Hospital; Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels; AZ Sint-Augustinus, Antwerp; Janssen Research & Development, Beerse, Belgium; Southampton University Hospitals NHS Trust, Southampton; Western General Hospital, Edinburgh; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; and Janssen Research & Development, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2200DOI Listing
April 2014

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.

J Clin Pharmacol 2013 Jan 24;53(1):14-20. Epub 2013 Jan 24.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270011433330DOI Listing
January 2013

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

Cancer Lett 2011 Dec 22;312(2):209-18. Epub 2011 Aug 22.

Radiothérapie moléculaire, Université Paris XI, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2011.08.011DOI Listing
December 2011

Exosome-based immunotherapy.

Cancer Immunol Immunother 2004 Mar 16;53(3):234-9. Epub 2004 Jan 16.

ERIT-M 02-08 INSERM, Department of Clinical Biology, Institut Gustave Roussy (IGR), 39 rue Camille Desmoulins, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-003-0472-xDOI Listing
March 2004

Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma.

Cancer Res 2004 Mar;64(6):2192-8

Immunology/Institut National de la Santé et de la Recherche Médicale ERM0208 and Immunotherapy Unit, Department of Pathology, Dermatology Unit, Institut Gustave-Roussy, 94805 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.can-03-2969DOI Listing
March 2004

[Exosomes and anti-tumour immunotherapy].

Bull Cancer 2003 Aug-Sep;90(8-9):695-8

Unité d'immunologie, Département de biologie clinique, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
December 2003

[NK cell-based immunotherapy: new prospects and involvement of dendritic cells].

Bull Cancer 2003 Aug-Sep;90(8-9):699-705

Unité Inserm ERIT-M 0208, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
December 2003

Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.

Blood 2002 Oct;100(7):2554-61

Département de Pédiatrie, the Unité d'Immunologie, the Unité de Thérapie Cellulaire, and the Service de Génétique, Département de Biologie Clinique, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.V100.7.2554DOI Listing
October 2002

Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.

Eur Cytokine Netw 2002 Jan-Mar;13(1):17-27

Unité d'Immunologie, Département de Biologie Clinique, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
September 2002

In vivo-targeted gene delivery using antibody-based nonviral vector.

Hum Gene Ther 2002 Jun;13(9):1101-14

INSERM U542/Paris-Sud University, Bâtiment Lavoisier, 16 avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/104303402753812502
Publisher Site
http://dx.doi.org/10.1089/104303402753812502DOI Listing
June 2002